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Biweekly oxaliplatin plus irinotecan and folinic acid-
modulated 5-fluorouracil: a phase II study in pretreated
patients with metastatic colorectal cancer
Pasquale Comellaa, Bruno Massiddad, Sergio Palmerie, Carlo Putzuf,
Vincenzo De Rosab, Francesco Izzoc, Francesco Fioreb, Rossana Casarettia
and Claudia Sandomenicoa
Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for
metastatic colorectal cancer, their toxicity profiles are not
overlapping, and both drugs have shown at least additivity
with folinic acid-modulated 5-fluorouracil (5FU). We carried
out this phase II study to assess the activity and toxicity of
a biweekly regimen including OXA plus IRI on day 1, and
levo-folinic acid (LFA) plus 5FU on day 2 (OXIRIFAFU) in
pretreated patients with metastatic colorectal cancer.
Forty-one patients, all previously treated with adjuvant and/
or palliative 5FU-based chemotherapy (16 of them already
exposed to IRI, OXA or both), were enrolled into this trial.
On the basis of sensitivity to previous treatment, 19
patients were considered as chemo-resistant and 14
patients as chemo-refractory. OXA 110mg/m2 (over 2 h)
and IRI 175mg/m2 (over 1 h) were delivered on day 1,
followed by LFA 250mg/m2 (2-h infusion) plus 5FU
800mg/m2 as intravenous bolus on day 2. Cycles were
repeated every 2 weeks. A total of 348 cycles were
delivered, with a median of nine cycles per patient
(range, 1–12 cycles per patient). Five complete and
13 partial responses were reported on 40 assessable
patients, giving a response rate of 45% [95% confidence
interval (CI), 29–62%]; eight of 19 (42%) resistant patients
and five of 14 (36%) refractory patients achieved a major
response, which was also obtained in four of eight (50%)
patients pretreated with IRI and in three of eight (38%)
patients pretreated with OXA. Grade 3 or higher
neutropenia occurred in 68% of patients, but febrile
neutropenia or infections affected only seven
(17%) patients. No episodes of grade 3 or higher
thrombocytopenia or anemia were recorded. Occurrence of
severe non-hematologic toxicities by patients were:
diarrhea, 34%; vomiting, 17%; peripheral cumulative
neuropathy, 15%; stomatitis, 10%; acute cholinergic
syndrome, 7%. Actually delivered dose intensities of all
three drugs resulted in about two-thirds of the
planned ones. After a follow-up of 39 months, median
progression-free survival was 7.5 months. Median overall
survival was 14.4 (95% CI, 10.4–18.4) months from the start
of OXIRIFAFU and 25.3 (95% CI, 18.1–32.5) months from
the diagnosis of metastatic disease. This OXIRIFAFU
triplet regimen was highly effective in resistant/refractory
colorectal cancer patients. A slight dose reduction of all
cytotoxic drugs could be advisable in order to improve
the tolerability of this regimen without jeopardizing its
activity. Anti-Cancer Drugs 17:985–992 c 2006 Lippincott
Williams & Wilkins.
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Introduction
The front-line treatment for patients with metastatic
colorectal cancer is still based on folinic acid (FA)
modulated 5-fluorouracil (5FU), alone or in combination
with either oxaliplatin (OXA) or irinotecan (IRI) [1,2].
Both combinations have shown superior activity (i.e.
significantly higher response rate and longer progression-
free survival) when compared with 5FU alone, although
only IRI-including regimens also improved the overall
survival [3–7]. Moreover, it appeared from retrospective
analyses that patients who were able to receive all three
active drugs during the course of their disease experi-
enced a longer survival [8,9]. This observation repre-
sented the rationale for assessing triplet regimens in
front-line. Indeed, several investigators have demon-
strated the feasibility and activity of different triplet
combinations in phase I–II studies [10–13].
On the other hand, the management of patients already
exposed to cytotoxic therapy is still debated. While
patients who have received a 5FU-based regimen after
primary surgery may be treated again with this drug at the
time of recurrence, provided that a long time interval
(more than 6 months) from the end of adjuvant treatment
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had elapsed, there is still uncertainty on how to manage
patients suffering from an early relapse or those previously
treated with a combination regimen in the adjuvant
setting. For these patients, there is an urgent need of
investigating new active cytotoxic regimens.
In a previous phase I study, we have already identified the
recommended doses of OXA plus IRI delivered on day 1,
and levo-folinic acid (LFA)-modulated bolus 5FU on day 2,
for a biweekly combination regimen [13]. This schedule of
administration was selected on the ground of some in-vitro
experiments on the HT29 human colon cancer cell line,
demonstrating a better growth-inhibitory effect when OXA
shortly preceded the exposure to SN-38 (the active
metabolite of IRI) [14]. On the other hand, the
assessment of the interaction between SN38 and 5FU on
different colon cancer cell lines, either sensitive (SNU-
C4) or resistant (SW620 and HT29) to 5FU, has shown
that a sequential (with SN38 before 5FU) rather than a
simultaneous exposure produced a synergistic or at least
additive effect in all cancer cell lines [15]. This
observation was also confirmed by in-vivo studies [16]. A
similar schedule-dependent interaction has been observed
for OXA followed by 5FU: this sequence was more
cytotoxic than the reverse one against the HT29 and
LoVo colon cancer cell lines, either sensitive or resistant to
5FU [17]. In addition, a short rather than long exposure to
5FU after a previous exposure to OXA was shown to be
more cytotoxic in several colon cancer cell lines [18].
Moreover, an in-vitro study on two human colon cancer cell
lines (SW620 and WIDR) reported the interaction of
different simultaneous exposures to OXA, SN38 and 5FU
modulated by FA (FUFA) [19]. In this study, the
OXA+FUFA combination was always synergistic, the
OXA+SN38 combination was either additive (when
SN38 was applied after OXA) or antagonistic (when SN38
was applied first), SN38+FUFA was always antagonistic,
while the triple exposure (OXA+SN38+FUFA) was
additive. Furthermore, the relative contribution of each
drug to the overall cytotoxicity of the triplet combination
was analyzed. From this analysis, the greatest contribution
was derived from OXA, while SN38 appeared to bring a
relatively modest addition to the combination effect.
The encouraging evidence of activity of this regimen that
we observed in the dose-finding trial [13] prompted us to
further investigate the safety and activity of this combina-
tion in patients already exposed to chemotherapy.
Patients and methods
Patient selection
Patients with histologically proven recurrent or metastatic
colorectal carcinoma were included in this study. At least
one bidimensionally measurable lesion should be present.
All patients should have received at least one 5FU-based
regimen, either in the adjuvant or in the palliative setting.
Previous exposure to OXA or to IRI was allowed.
According to previous drugs exposure, disease status for
each patient was classified as chemo-resistant (relapse
within 6 months from the end of adjuvant chemotherapy
or disease progression within 3 months from the
discontinuation of palliative chemotherapy) or chemo-
refractory (relapse during adjuvant chemotherapy or
disease progression during palliative chemotherapy).
Other eligibility criteria were: age between 18 and 75 years;
performance status r2 of the Eastern Cooperative
Oncology Group scale; life expectancy >3 months; dis-
continuation of previous chemotherapy for at least 1 month;
normal bone marrow reserve, with an absolute neutrophil
count Z2000/ml and a platelet count Z100000/ml; and
adequate hepatic (bilirubin serum level <1.5mg/dl; ASAT
and ALAT <2 upper normal limit), and renal function
(creatinine clearance >60ml/min). The study protocol was
approved by the Independent Ethical Committee of the
National Tumour Institute of Naples. All patients were
informed of the investigational nature of this study and each
patient provided written consent before registration.
Administration of treatment
OXA 110mg/m2 (intravenously over at least 2 h) and IRI
175mg/m2 (intravenously over 1h) were delivered on day 1.
LFA 250mg/m2 (intravenously over 2h), followed by 5FU
800mg/m2 intravenous bolus, was administered on day 2.
The initial dosage of all three cytotoxic drugs was reduced
by 25% in elderly patients, in patients previously exposed to
pelvic radiotherapy or in patients who had already suffered
from severe hematologic and/or non-hematologic toxicity on
previous adjuvant/palliative chemotherapy. Patients received
a standard anti-emetic premedication, with HT3-receptor
antagonists and steroids, on the first day of each cycle.
Systematic prophylaxis for early cholinergic symptoms due
to IRI was not performed. Similarly, no prophylaxis was
given for the occurrence of late diarrhea. Patients, however,
were carefully instructed to take loperamide orally as soon as
the first stool modification occurred. Granulocyte colony-
stimulating factors were not permitted unless in the
presence of febrile neutropenia.
Treatment was delivered every 2 weeks until a major
response was achieved; in this case, at least eight courses,
and a maximum of 12 cycles were planned. Therapy was
discontinued in the case of documented disease progres-
sion, occurrence of disease complications, unacceptable
toxicity, patient’s refusal or when it was believed to be for
the patient’s best interest.
Recycling rules and doses reduction
Courses were repeated every 2 weeks in the presence of an
absolute neutrophil count Z 1500/ml and a platelet count
Z 100 000/ml, and recovery of any extra-hematologic
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toxicity. Otherwise, treatment was postponed for 1 or 2
weeks until recovery. If recovery required more than 2
weeks, the patient went off study. In the presence of
World Health Organization (WHO) grade 4 hematologic
toxicity, or in the presence of grade Z 3 non-hematologic
toxicity, the subsequent cycles were administered, after
recovery of side-effects, with a 25% dose reduction of all
cytotoxic drugs. In the cases of grade 3 neurotoxicity, OXA
was reduced by 25%; if there was no recovery at the time
of recycling after this dose reduction, OXA delivery was
discontinued.
Evaluation of toxicity
For the assessment of acute hematologic toxicity, blood
cell count was performed weekly, and two times a week in
the case of grade 4 toxicity. Blood cell count with absolute
neutrophil count and platelet count, and a full biochem-
istry profile (serum dosage of bilirubin, ASAT and ALAT,
g-glutamyltranspeptidase, alkaline phosphatase, lactic
dehydrogenase, albumin and total protein, urea and
creatinine, and urinalysis) was performed at each cycle.
Patients were checked to detect signs of neurotoxicity
before initial treatment and at every cycle thereafter. The
acute toxicity was classified according to WHO toxicity
criteria [20]. Neurologic toxicity was graded according to
a specific Le´vi scale [21].
Evaluation of activity
Initial staging work-up included history and physical
examination, routine biochemistry, blood cell count,
carcinoembryonic antigen serum level determination,
chest X-ray and abdominal ultrasound scan. Bidimension-
ally measurable indicator lesions were assessed by
computed topographic scan, or magnetic nuclear reso-
nance imaging. Subjective symptoms, body weight,
physical examination and performance status were
recorded before each treatment cycle. All initially
abnormal tests were repeated after every four cycles.
Responses were classified according to standard WHO
criteria [20]. To classify for response, the reduction of
tumor burden was confirmed on two consecutive assess-
ments, 2 months apart. Duration of response was
measured from the first time it was documented to the
date of recurrence or last follow-up.
Evaluation of progression-free and overall survival
Progression-free survival was calculated from the date of
initial OXIRIFAFU therapy to the date or progression,
death or last follow-up. Overall survival was calculated both
from the date of the first documentation of metastatic
disease, and from the start of OXIRIFAFU treatment, to the
date of death or last-follow-up. Survival curves were
estimated with the Kaplan and Meier method [22].
Definition of the sample size
The study population was defined according to the Simon
two-stage minimax design [23]. A 20% response rate was
the minimum activity of interest for rejecting this
regimen, while a 40% response rate was the alternative
hypothesis. Therefore, at least five responses on the first
18 patients and at least 10 responses on 33 patients were
required to accept this hypothesis with a 0.05 a error.
Results
Patient characteristics
From January 2001 to October 2005, 41 patients entered
this trial (Table 1). Most patients had already received
adjuvant (73%) treatment and/or one (59%) or two (12%)
lines of palliative chemotherapy. According to previous
drugs exposure, 33 (80%) patients were classified chemo-
resistant (19 patients) or chemo-refractory (14 patients).
Eight patients had already received an OXA-based
regimen and eight patients an IRI-containing treatment.
Almost half the number of the patients has two or more
sites of disease and the liver was the most common site of
metastasis. One patient was enrolled in this study
without evidence of disease after surgical resection of
liver metastasis.
Acute toxicity
A total of 348 cycles were delivered, with a median of
nine courses per patient (range, 1–12 courses per
Table 1 Main patient characteristics
Characteristics Number Percentage
Total patients 41 100
Males 23 56
Females 18 44
Median age (range) (years) 56 (30–74)
Primary site
Colon 28 68
Rectum 13 32
Previous surgery 40 98
Previous adjuvant 5FU 27 66
Previous adjuvant FOLFIRI 3 7
Previous one line of palliative CT 24 59
Previous two lines of palliative CT 5 12
Previous Irinotecan exposure 8 20
Previous Oxaliplatin exposure 8 20
Chemo-sensitive 8 20
Chemo-resistant 19 46
Chemo-refractory 14 34
Performance status
0 22 54
1–2 19 46
Weight loss 8 20
Disease-related pain 17 41
Number of disease sitesa
1 23 56
2 13 32
3+ 4 10
Site of disease
Liver 25 61
Lung 13 32
Nodal 9 22
Peritoneal 7 17
Local recurrence 6 15
Bone 2 5
CEA basal value >5 ng/ml 28 68
CEA basal value Z100 ng/ml 13 32
aOne patient was disease-free after liver resection. CT, computed tomography;
CEA, carcinoembryonic antigen.
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patient). Twenty-six (63%) patients received at least
eight cycles and nine (22%) patients received 12 cycles.
Thirty patients discontinued their treatment according to
the protocol’s rules, four patients went off study because
of toxicity or refusal (two patients each) and four patients
for disease complications. In three cases, the decision to
interrupt the treatment early was taken by the attending
physician.
No toxic death occurred. Table 2 reports the worst
hematologic toxicity registered for each patient during
treatment. Severe neutropenia affected 28 (68%) pa-
tients. In detail, grade 3 neutropenia was detected in 12
(29%) patients and grade 4 neutropenia in 16 (39%)
patients. Febrile neutropenia or infection, however,
affected only seven patients in all. It is relevant to note
that no severe anemia or thrombocytopenia occurred in
any patient during treatment. Main non-hematologic
toxicity is shown in Table 3. Diarrhea was the most
common side-effect, affecting 80% of patients; it was
severe in 14 (34%) patients, and required hospitalization
and rehydration in five cases. Some gastric disturbance
was reported by 28 (68%) of patients, but it was severe in
only seven (17%) patients.
OXA-induced neuropathy occurred in 23 (56%) patients
and it was severe in six (15%) patients. As expected, this
toxicity was dose-related, because it affected four of 18
(22%) patients receiving a cumulative dosage of OXA
exceeding 800mg/m2. Three additional patients suffered
from acute paresthesia or laringospasm during an OXA
infusion, but this side-effect was subsequently prevented
by prolonging the infusion over 6 h.
According to protocol rules, the dosage of at least one of
the cytotoxic drugs was reduced in 28 of 41 (68%)
patients, from initial (eight patients) or subsequent
cycles (20 patients); therefore, the median absolute
(and relative) dose intensity was 34mg/m2/week (62%)
for OXA, 54mg/m2/week (61%) for IRI and 248mg/m2/
week (62%) for 5FU.
Activity
Among 40 patients with evidence of disease, five
complete remissions and 13 partial remissions were
achieved, giving an overall response rate of 45% [95%
confidence interval (CI), 29–62%] according to an intent-
to-treat analysis (Table 4). In all but one case, patients
achieving a complete remission had their disease
confined to one site only, which was the liver in four
cases. One additional patient, considered in partial
remission after eight cycles, was rendered disease-free
by liver resection of residual metastatic deposits. Major
responses were documented after a median time from
initial therapy of 3 months (range, 2–8 months) and they
had a median length of 7.9 months (range, 2.2–21.4
months).
Six patients showed a tumor shrinkage that did not
qualify for a major response; however, three of these
patients also showed a 50% or greater drop of their
initially abnormal serum carcinoembryonic antigen value.
Six patients achieved a sustained stable disease for 6
months or more (Table 4).
Activity of this regimen appeared not related with the
sensitivity to the previous cytotoxic drug exposure.
Indeed, eight of 19 (42%) chemo-resistant and five of
14 (36%) chemo-refractory patients achieved a major
response. Of note, four of eight patients previously
exposed to IRI and three of eight already treated with
OXA subsequently showed a response to OXIRIFAFU.
No substantial difference of activity was seen between
patients with only one disease site (48%) and patients
with two or more disease sites (41%).
Follow-up
After a median follow-up of 39 months, 35 patients
progressed and 26 died. The estimated median progres-
sion-free survival was 7.5 months (95% CI, 5.0–10.0
Table 2 Hematologic toxicity (WHO grade) by patients (n=41)
Toxicity Number of patients Percentage
1 2 3 4 3+4
Neutropenia 2 5 12 16 68
Febrile neutropenia/
infection
0 6 1 0 2
Platelets 5 5 0 0 0
Anemia 11 5 0 0 0
WHO, World Health Organization.
Table 3 Non-hematologic toxicity (WHO grade) by patients (n=41)
Toxicity Number of patients Percentage
1 2 3 4 3+4
Nausea/vomiting 14 7 5 2 17
Diarrhea 10 9 9 5 34
Stomatitis 5 0 2 2 10
Alopecia 6 3 10 0 24
Chronic neuropathya 13 4 6 0 15
Cholinergic syndrome 0 3 3 0 7
Acute dysesthesia 1 1 1 0 3
Hepatic 3 0 0 0 0
aAccording to the Le´vi’s scale.
WHO, World Health Organization.
Table 4 Activity reported with OXIRIFAFU
Responses Number Percentage
Complete response 5 13
Partial response 13a 32
Minor response 6b 15
Stable disease 6 15
Progression 10 25
Assessable patients 40c 100
aOne patient was rendered disease-free after liver resection.
bThree of six patients showed a 50% or greater drop of baseline abnormal CEA
value.
cNo evidence of disease in one patient at baseline.
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months) (Fig. 1). Median overall survival was 14.4 months
(95% CI, 10.4–18.4 months) from the commencement of
OXIRIFAFU (Fig. 2), while it was 25.3 months (95% CI,
18.1–32.5 months) from the documentation of the
metastatic disease (Fig. 3).
Discussion
The prognosis of patients with metastatic colorectal
cancer is invariably poor, because only palliative treat-
ments are available for this disease [1,2]. Some new
cytotoxic and biologic drugs, however, have recently
entered into the clinical practice for treating these
patients [2]. Namely, IRI and OXA, both associated with
5FU, have shown a high activity in the first-line
treatment [3–7], and patients receiving all these active
drugs during the course of their disease have shown a
prolonged survival [8,9]. A substantial proportion of
metastatic patients are, however, unable to receive the
three drugs sequentially, mainly due to a worsening of
clinical status after the front-line treatment that pre-
cludes the delivery of further cytotoxic chemotherapy.
This observation has prompted some investigators to
assess the feasibility of an up-front triplet regimens in
phase I–II studies [10–12,24]. In all these trials, short-
term infusional 5FU has been used. In detail, Masi et al.
[10] delivered OXA 100mg/m2, IRI 175mg/m2 and
leucovorin 200mg/m2 followed by a 48-h infusion of
5FU 3800mg/m2. An exciting 67% response rate has been
reported on mainly chemo-naive patients. A grade 4
neutropenia, however, was registered in 55% of patients,
12% of whom had also a febrile neutropenia. In addition,
grade 3 diarrhea affected 21% of patients. Similarly, Calvo
et al. [11] reported a 69% response rate on 26 patients
treated with a 1-day regimen including OXA 120mg/m2,
IRI 250mg/m2, 5FA 500mg/m2 and FU 2600mg/m2
infused over 24 h. Moreover, the combination of IRI
150mg/m2 on day 1, OXA 65mg/m2 on day 2, followed by
an leucororin-modulated 5FU bolus plus 22-h infusion for
2 consecutive days (LV5FU2) every 2 weeks has been
assessed by Souglakos et al. [12] on 31 patients previously
unexposed to palliative chemotherapy, achieving a 58%
response rate.
The impact on survival of an up-front triple combination,
however, is still unclear. Indeed, while a significant
survival prolongation was achieved in one study compar-
ing a triplet (FOLFOXIRI) with a doublet (FOLFIRI)
regimen [25], another trial reported absolutely identical
survival outcome for patients treated either with doublet
or with triplet therapy [26].
Our trial is the only one among those assessing the
efficacy of a triplet combination that incorporated an
Fig. 1
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intravenous bolus of 5FU. The choice of this schedule
was supported by the already mentioned in-vitro
evidence [14–18] and also by our own previous dose-
finding trial [13]. The results of the present phase II
study confirm that all three cytotoxic drugs can be safely
combined in close sequence in a 2-day cycle. Severe
diarrhea was the main non-hematologic toxicity of this
treatment, affecting 34% of treated patients. This figure,
however, is comparable to that reported by Souglakos et al.
[26] (28%) and only slightly greater than that observed by
Falcone et al. [25] (19%). On the contrary, grade 3 or
higher neutropenia affected more patients in our
experience (68%) than in the above-mentioned trials
(35 and 46%, respectively). This side-effect, however,
was often a mere laboratory finding, detected by the
weekly blood cell counts performed in our trial, and it
usually had no clinically meaningful consequences.
Indeed, febrile neutropenia and/or infection occurred in
seven patients in all.
On the other hand, the cautious approach we observed for
preventing, or the dose reduction we applied after the
occurrence of severe toxicity, translated in a dose
intensity of all three drugs corresponding to about 60%
of the planned ones. It should be noted, however, that
the actual dose intensity of OXA was only moderately
lower than that usually achieved when this drug is
combined with bolus or infusional 5FU [7,27]. Moreover,
our regimen was very active despite this dose reduction.
This finding confirms the in-vitro observation, which
highlighted the greatest contribution of OXA to the
overall cytotoxicity of the triplet combination [19], and
suggests that a slight dose reduction of this regimen in
further clinical evaluation could not jeopardize its activity.
The achievement of a major response in 18 (45%)
patients, associated with a minor shrinkage or disease
stabilization reported in 12 (30%) further patients,
demonstrated that this regimen was highly effective in
metastatic colorectal cancer. Of interest was the response
rate observed in patients affected by a disease poorly
sensitive to previous chemotherapy and in those already
exposed to one or two components of the combination.
Therefore, this regimen deserves to be further explored
in this subset of patients. The duration of responses and
the progression-free survival was also unusually long in
this trial, confirming that a good disease control was
achieved with the treatment on study. The median
survival time was not negligible, because it was 14.4
months from the start of the present treatment and it was
Fig. 2
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in excess of 2 years from the date the metastatic disease
was initially documented. This observation is an indirect
confirmation that patients treated with all available
cytotoxic drugs may obtain an unusually long overall
survival.
In conclusion, the toxicity profile of our OXIRIFAFU
regimen was acceptable and its activity was impressive in
a population of heavily pretreated patients. Therefore, we
believe it worthwhile to further investigate the effec-
tiveness of this regimen in metastatic colorectal cancer
patients, i.e. in patients with early recurrence after
adjuvant or palliative FU-based chemotherapy.
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